According to Fortune Business Insights, Japan's tardive dyskinesia therapeutics market was valued at approximately USD 24.3 million in 2022 and is expected to climb to USD 38.6 million in 2023, eventually reaching around USD 162.1 million by 2030. This trajectory implies a compound annual growth rate (CAGR) of roughly 22.7% across the 2023–2030 forecast window — a pace that reflects both the small current base of the market and strong underlying demand drivers.
Tardive dyskinesia is a movement disorder that develops as an adverse reaction to certain psychotropic medications, particularly antipsychotics. It tends to occur more frequently with older, first-generation antipsychotics than with newer second-generation drugs used to manage psychiatric conditions. Because there is no outright cure, treatment focuses on symptom management using VMAT2 (vesicular monoamine transporter-2) inhibitors — namely valbenazine and deutetrabenazine — both of which secured U.S. FDA approval back in 2017.
Japan's Regulatory Landscape
Japan's path has lagged other major markets. Only valbenazine has received approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and that approval came in 2022 — five years after the drug's U.S. clearance. Deutetrabenazine remains unapproved in Japan, though the report notes it has shown favorable long-term safety and efficacy data, suggesting future approval potential. Europe's regulatory stance on VMAT2 inhibitors for this indication is similarly inconsistent, underscoring how uneven global access to TD treatment remains.
A pivotal industry milestone came in June 2022, when Mitsubishi Tanabe Pharma Corporation launched DYSVAL (valbenazine) 40mg capsules — the first medication approved in Japan specifically for tardive dyskinesia. The approval followed a collaboration between Neurocrine Biosciences and Mitsubishi Tanabe Pharma, and DYSVAL's inclusion on Japan's National Health Insurance Drug Price List has further strengthened its commercial outlook.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/japan-tardive-dyskinesia-therapeutics-market-109010
Pandemic Disruption and Recovery
The COVID-19 pandemic slowed the market's early growth. Lockdowns reduced hospital visits and disrupted routine psychiatric care, delaying diagnoses and treatment for patients on antipsychotic regimens. Data cited in the report indicate that the share of newly treated major depressive disorder patients under age 20 in Japan rose from 3.7% pre-pandemic to 4.8% during the pandemic period, pointing to broader strain on mental health services. Pharmaceutical companies also faced slower regulatory and commercial timelines as non-emergency healthcare operations were curtailed. As restrictions eased, regulators resumed review of pending drug approvals, paving the way for DYSVAL's 2022 launch.
Growth Drivers and Restraints
Two intertwined trends are pushing the market forward. First, Japan's psychiatric disorder burden is significant — a 2023 study referenced in the report found anxiety and depression prevalence among older Japanese adults at 43.9% and 69.4%, respectively. Second, antipsychotic use itself is rising: the proportion of Japanese patients on second-generation antipsychotics reportedly grew from 28.9% to 70.3% over the past two decades, according to research published in 2021. Since prolonged antipsychotic use is a key risk factor for TD, this expanding patient pool is expected to sustain therapeutic demand.
Counterbalancing these tailwinds is a persistent lack of awareness about TD among both patients and healthcare providers in Japan, which limits diagnosis and treatment uptake. Japan's comparatively strict regulatory environment has also kept the pool of approved therapies narrower than in the United States, constraining near-term market expansion.
Market Segmentation
By drug: Valbenazine led the market in 2022, unsurprising given it is currently the only approved TD therapy in Japan. Deutetrabenazine and a pipeline "others" category — reflecting ongoing R&D investment from established players — round out the segment, with future launches anticipated to broaden the competitive field.
By distribution channel: Hospital pharmacies dominated in 2022, consistent with TD drugs being prescription-only "ethical drugs" typically routed through hospital and clinic supply chains in Japan. Retail pharmacies are projected to grow as well, supported by rising patient volumes for neurological disorder treatment, but at a comparatively slower pace.
Competitive Landscape
Mitsubishi Tanabe Pharma Corporation held a dominant position in 2022, a direct result of holding Japan's sole regulatory approval for a TD therapy. Other companies with a stake in the broader landscape include Teva Pharmaceutical Industries (marketing Austedo/deutetrabenazine, though guidelines for deuterated drugs remain nascent in Japan), Neurocrine Biosciences, SOM Biotech, Luye Pharma Group, and Janssen Pharmaceutical K.K., which co-promotes valbenazine locally alongside Mitsubishi Tanabe.
Outlook
With a single approved therapy currently on the market, Japan's TD therapeutics sector has considerable room to expand as awareness improves, additional drugs clear regulatory hurdles, and the underlying psychiatric and antipsychotic-use trends continue. Fortune Business Insights projects sustained double-digit growth through 2030, contingent on regulatory progress and broader clinical adoption.